Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 440 results for "kexin"

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibito...

Summary Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. The main objective ... Individual.com, 5 days ago
[x]  

3 images for "kexin"

European Pharmaceutical Review, 2 days ago
Pharmaceutical Journal, 3 weeks ago
Pharmaceutical Journal, 1 month ago

Speed Skating - Fan maintains 500m World Cup winning run in Montreal

China's Fan Kexin continues to set the pace in the early part of the new World Cup short track speed skating season after winning the 500m final in Montreal. . View photo Kexin Fan, February 2012 The Olympic 1000m silver medallist climbed ...
 Yahoo! UK and Ireland Eurosport1 week ago Two World silvers for Christie  Sky Sports1 month ago

Sichuan Kexin Mechanical and Electrical Equipment actual controller proposes 2014 dividend payment

Thomson Reuters is the world's largest international multimedia news agency, providing investing news , world news , business news , technology news , headline news, small business news, news alerts, personal finance , stock market , and mutual ...
 Reuters UK2 months ago
CHINAdaily

China's rural couriers ride wave of e-commerce expansion

[Photo/IC] CHANGCHUN - Each morning at 8 am, Wang Kexin puts on his helmet and leg guards and hops on a motorcycle to begin his workday. The 31-year-old goes door to door through villages in Maolin township in Northeast China's Jilin province to ...
 CHINAdaily Europe1 month ago Rural couriers ride wave of e-commerce expansion  China Economic Net1 month ago ALIBABA : China's rural couriers ride wave of e-commerce expansion  4 Traders1 month ago Shopping online proves a boon for rural residents  Shanghai Daily4 weeks ago
[x]  

Connections with Nature and Environmental Behaviors

by Liuna Geng, Jingke Xu, Lijuan Ye, Wenjun Zhou, Kexin Zhou The influence of environmental attitudes on environmental behaviors has long been discussed. However, few studies have addressed the foundation of such attitudes. In the present study, we ...
 Plosone.org6 days ago

Letter From Le May and Cariou Regarding Article, "Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent

Letter From Le May and Cariou Regarding Article, Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein ReceptorDependent and ...
 Circulation: Cardiovascular Interventions2 weeks ago Response to Letter Regarding Article, "Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms"  Circulation: Cardiovascular Interventions2 weeks ago
European Pharmaceutical Review

EMA committee recommends marketing authorisation for Amgen's Repatha for high cholesterol treatment

Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Repatha (evolocumab) recommending approval for use in certain ...
 PharmaBiz2 hours ago Amgen Receives Positive Opinion For Use Of Repatha (Evolocumab) For The Treatment Of High Cholesterol  BioSpace2 days ago Amgen (AMGN) First To Win EU Support For New Kind Of Cholesterol Drug 5/22/2015  ClinicSpace3 days ago Pending EC decision: Repatha, evolocumab, Opinion date: 21-May-2015  European Medicines Agency3 days ago
[x]  

Amgen (AMGN), Sanofi (SAN.PA) in Race to Get European Green light for Anti-Cholesterol Drugs 5/21/2015

May 20, 2015 By Alex Keown , BioSpace.com Breaking News Staff LONDON Amgen ( AMGN )'s cholesterol drug Repatha could be recommended for approval in Europe later this week, which would give the California-based Amgen a leg up over rival ...
 ClinicSpace2 days ago Amgen Beats Sanofi to Market with EU Hurdle for Anti-Cholesterol Drug  BioSpace2 days ago Amgen (AMGN) Beats Sanofi (SAN.PA) to Market with EU Hurdle for Anti-Cholesterol Drug 5/22/2015  ClinicSpace2 days ago Amgen, Sanofi in Race to Get European Green light for Anti-Cholesterol Drugs  BioSpace4 days ago
European Pharmaceutical Review

Global Dyslipidemia Treatment Market Will Double by 2023

- The global treatment market for dyslipidemia will more than double in value from $15.4 billion in 2013 to an estimated $37.9 billion by 2023, representing a Compound Annual Growth Rate (CAGR) of 9.4%, according to research and consulting firm ...
 PharmaceuticalProcessing4 days ago Dyslipidemia treatment market value will approach $38 billion by 2023, says GlobalData  European Pharmaceutical Review4 days ago

Lipid lowering for primary prevention of stroke in older adults?

Graeme J Hankey , professor of neurology 1 , consultant neurologist 2 , research affiliate and honorary senior research fellow 3 1 School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Institute of Medical Research, ...
 British Medical Journal6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less